GlassScriptPhysician profile
Robert G Strathman
NPI 1548349566
$1,297.24
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $325 · 2021: $451 · 2022: $272.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.86 | 2019-2022 | |
| Therapeuticsmd, INC. | $120.11 | 2020 | |
| Exeltis, USA INC. | $101.37 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $94.82 | 2022 | |
| Hologic Sales and Service, LLC | $42.05 | 2019-2021 | |
| Evofem Biosciences, INC. | $21.31 | 2022 | |
| Lupin INC. | $16.97 | 2020 | |
| Duchesnay USA Incorporated | $12.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Strathman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.